Wedbush Upgrades Apogee Therapeutics, Lifts Price Target to $18.00

Wedbush Securities has raised its price target on Apogee Therapeutics (APGE) to $18.00 per share, up from $15.00, following a review of the company’s upcoming clinical milestones. The investment firm highlighted the advancement of APG-1252, Apogee’s investigational therapy for low-grade glioma, as a key driver behind the upgrade. The drug recently entered Phase 2b clinical testing, with top-line data expected in late 2026. The price target increase signals a more optimistic outlook on Apogee’s near-term development trajectory. The company’s market capitalization stands at approximately $480 million, with APGE trading at around $13.20 prior to the announcement. The new target implies a potential 35% upside from current levels, reflecting improved expectations for regulatory and commercial viability. Market reaction has been modest, with APGE shares rising 4.7% in early trading following the report. The move is likely to attract attention from institutional investors focused on small-cap biotechnology with near-term clinical catalysts. Analysts note that the firm’s capital efficiency and debt-free balance sheet strengthen its ability to execute on development plans without significant dilution. While the upgrade is positive, Wedbush maintains a 'neutral' rating, indicating cautious optimism. The company remains in a high-risk, high-reward segment of the healthcare sector, where outcomes are heavily dependent on clinical trial success. Investors should monitor data readouts from the Phase 2b study, as well as potential partnerships or funding developments in the second half of 2026.